Aug 31, 2022Alpha Tau Medical to Participate in Upcoming September Investor Conferences JERUSALEM, August 30, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer...
Aug 26, 2022Alpha Tau Medical Announces Second Quarter 2022 - Financial Results and Provides Corporate Update-Received FDA Conditional Investigational Device Exemption (IDE), whose conditions have since been satisfied, to initiate a pivotal trial...
Aug 22, 2022Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment PlanningJERUSALEM and CLEVELAND, Aug. 22, 2022 -- Today, Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative...
Jul 6, 2022Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical TrialsAlpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials
Jun 23, 2022Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™ JERUSALEM, June 22, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer...